BioNTech Investor Presentation Deck

Oncology: Potential To Tackle Multiple Diseases With Different Therapeutic Modalities Next Generation Immunomodulators iNeST / Fix Vac Induces multi-specificity, multi-valency, high tumor-antigen specific cell responses with unprecedented potency • mRNA Cancer Vaccines 22 4 Phase 2 randomized trials (2 iNeST and 2 FixVac) Cell Therapies Next Gen CAR-T Cell / Neoantigen-based T Cell / Personalized TCR-T Cell Therapy ● 2 Phase 1 FIH trials started in Feb. and Apr. 2021 Targeted Cancer Antibodies ● Antibodies ● Novel cancer cell surface targets for underserved high medical need cancers CA 19-9 antibody in 1L pancreatic cancer in Phase 1/2 trial + Small Molecule Immunomodulators TLR-7 Agonist ● Potently modulates innate immunity Phase 1 trial CAR, Chimeric antigen receptor; TCR, T Cell receptor; FIH, First-in-human; CA 19-9: Cancer antigen 19-9; 1L, first-line; TLR-7, Toll-like receptor 7; CPI, Check-point Inhibitor ● Bispecifics Next-generation checkpoint inhibitors to address a broad range of cancers Phase 1/2 trials of 2 bispecific antibodies 1 Phase 2 randomized trial ● ● • ● Ribocytokines, RiboMabs mRNA encoded cytokines or antibodies with potential for improved properties and half life Potential to amplify vaccines and CPIs ● 2 Phase 1 FIH RiboCytokine trials Ribologicals 2 Phase 1 FIH RiboMab trials Multiple product opportunities with unique combination potential in clinical testing BIONTECH

View entire presentation